Literature DB >> 9017517

HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease.

V G Cabana1, J R Lukens, K S Rice, T J Hawkins, G S Getz.   

Abstract

High density lipoprotein (HDL) levels decrease during the acute phase response (APR). We have used the APR model of rabbit, baboon, and mouse to study the factors that influence HDL level. In the baboons and rabbits there was massive hypertriglyceridemia, triglyceride enrichment of HDL (60-80% of core lipids), decreases of HDL-cholesterol and apolipoprotein (apo)A-I (to 10% of baseline), and increases of apoA-I in the non-lipoprotein bottom fraction suggesting dissociation of apoA-I from the particles. Detailed analyses of serum amyloid A (SAA)-rich HDL done in the rabbit revealed large, triglyceride-enriched (> 60% of core lipids) particles containing > 95% SAA. These particles had a high surface to core ratio (13.4 +/- 1.94, control = 3.0 +/- 0.12) and a very high protein (79.71 +/- 5.25 weight %, control = 37.2 +/- 0.43) proportion, large (r = 5.95 nm) when examined by non-denaturing gradient electrophoresis but small when examined by electron microscopy (r = 4.2 nm). In the mouse there was no hypertriglyceridemia, no triglyceride enrichment of HDL, no decrease of HDL cholesterol. ApoA-I decreased to about 61.4% of baseline but did not increase in the bottom fraction although large but dense SAA-enriched HDL particles were also produced. These results suggest that hypertriglyceridemia, triglyceride-enrichment of HDL, and dissociation of apoA-I from the particles, possibly by displacement of apoA-I by SAA, are important factors in the decline of HDL during the APR. Whether differences in triglyceride metabolism account for the differences in the HDL response in the species studied requires further experimentation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9017517

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  33 in total

1.  4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.

Authors:  Geoffrey D Wool; Veneracion G Cabana; John Lukens; Peter X Shaw; Christoph J Binder; Joseph L Witztum; Catherine A Reardon; Godfrey S Getz
Journal:  FASEB J       Date:  2010-09-27       Impact factor: 5.191

Review 2.  Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection.

Authors:  Michael J Haas; Arshag D Mooradian
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

3.  SAA: a link between cholesterol efflux capacity and inflammation?

Authors:  Michael J Thomas; Mary G Sorci-Thomas
Journal:  J Lipid Res       Date:  2015-06-15       Impact factor: 5.922

Review 4.  HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders.

Authors:  G S Getz; G D Wool; C A Reardon
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

5.  Impact of individual acute phase serum amyloid A isoforms on HDL metabolism in mice.

Authors:  Myung-Hee Kim; Maria C de Beer; Joanne M Wroblewski; Richard J Charnigo; Ailing Ji; Nancy R Webb; Frederick C de Beer; Deneys R van der Westhuyzen
Journal:  J Lipid Res       Date:  2016-03-27       Impact factor: 5.922

Review 6.  Unraveling the complexities of the HDL lipidome.

Authors:  Anatol Kontush; Marie Lhomme; M John Chapman
Journal:  J Lipid Res       Date:  2013-03-30       Impact factor: 5.922

7.  Characterization of metabolic and inflammatory profiles of transition dairy cows fed an energy-restricted diet.

Authors:  Giulia Esposito; Emiliano Raffrenato; Somwe D Lukamba; Mounir Adnane; Pete C Irons; Paul Cormican; Taurai Tasara; Aspinas Chapwanya
Journal:  J Anim Sci       Date:  2020-01-01       Impact factor: 3.159

8.  Bile acid-induced inflammatory signaling in mice lacking Foxa2 in the liver leads to activation of mTOR and age-onset obesity.

Authors:  Irina Mikhailovna Bochkis; Soona Shin; Klaus Hermann Kaestner
Journal:  Mol Metab       Date:  2013-08-24       Impact factor: 7.422

Review 9.  High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.

Authors:  Georges Khoueiry; Mokhtar Abdallah; Faisal Saiful; Nidal Abi Rafeh; Muhammad Raza; Tariq Bhat; Suzanne El-Sayegh; Kamyar Kalantar-Zadeh; James Lafferty
Journal:  Int Urol Nephrol       Date:  2013-02-27       Impact factor: 2.370

Review 10.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.